LakeShore Biopharma Announces Fiscal Year 2025 Financial Results

SEC Filing 6-K (0001213900-25-069883)

LakeShore Biopharma Co., Ltd reported its financial results for the fiscal year ended March 31, 2025. The company achieved a 7.2% year-over-year growth in total revenue, reaching RMB615.0 million. Gross profit increased by 11.3% to RMB507.2 million, with the gross margin improving to 82.5% from 79.5% in the previous year. Total operating expenses decreased by 34.2% to RMB593.5 million. The company reported a net loss of RMB100.0 million, significantly lower than the RMB433.5 million loss in FY2024. Adjusted EBITDA improved to RMB0.6 million from a loss of RMB236.4 million in the previous year. The company attributed the improved results to strategic resource allocation, cost control measures, and enhanced corporate governance. LakeShore Biopharma also provided a revenue outlook for FY2026, anticipating total revenue between RMB550 million and RMB650 million.